Kornimate/medical-research-clean huggingface dataset:
an open-label trial to determine increased red blood cell production in subjects with anemia of chronic disease

Conditions: Anemia of Chronic Disease

Summary: the objective of this study is to measure the change in blood values after the administration of an amino acid based erythropoietin stimulating system.


Eligibility criteria:
inclusion criteria: 1. m/f patients 18 years old and over, non-pregnant/lactating 2. hemoglobin \< 10 female,\<11 male 3. ferritin \> upper limit of normal for lab indicative of chronic anemia 4. anemia of chronic disease 5. crt. \< 3.0 exclusion criteria: 1. currently taking other amino acid formulations. 2. pregnant or unwilling to use adequate birth control for the duration of the study. 3. excessive alcohol or illicit drug use. 4. unwilling or unable to sign informed consent. 5. myocardial infarction within the last 6 months. 6. patients ever having taken or currently taking an erythropoietin medication. 7. iron deficiency (add criteria). 8. on dialysis. 9. malignancy other than non-melanoma skin cancer within the last 5 years. if has such malignancy, must have documentation of no recurrence for at least 5 years. 10. liver cirrhosis (add criteria).
accurate prostate cancer following using low-field mri (low-prism)

Conditions: Prostate Cancer

Summary: this study compares the effectiveness of low-field mri (0.55t) with high-field mri (3t) in prostate cancer screening and image quality. it consists of three phases: optimizing the low-field mri protocol with healthy volunteers, evaluating image quality in patients with metallic artifacts (like hip prostheses), and assessing low-field mri in patients with suspicious prostate lesions found on high-field mri.

this study aims to compare the effectiveness of low-field mri (0.55t) with traditional high-field mri (3t) in prostate cancer screening and image quality improvement. the study is conducted in three phases: first, a pilot study with healthy volunteers to optimize the low-field mri protocol; second, an evaluation of image quality between the two types of mri in patients with metallic artifacts, particularly due to hip prostheses; and finally, the assessment of low-field mri in patients with suspicious prostate lesions on high-field mri (3t). the goal is to find an accessible solution for prostate cancer screening while maintaining or improving image quality.

Eligibility criteria:
inclusion criteria: work package1 (wp): 0.55t mri protocol development * healthy male volunteers aged 18 and above. * agree to be contacted for incidental findings * signed informed consent wp2: 0.55t prostate mri with patients with metallic implant(s) * adult men (≥18 y.o) with 3t mri reported as sub-diagnostic due to metallic implants * signed informed consent wp3: 0.55t prostate mri with patients with suspicious lesion(s) * adult men (≥18 y.o) * pi-rads 4/5 lesions detected on 3t mri, schedules for targeted biopsy * signed informed consent exclusion criteria: wp1: 0.55t mri protocol development * individuals with a history of prostate cancer * mr contraindications as listed in the mr safety screening form wp2: 0.55t prostate mri with patients with metallic implant(s) * contraindications as per md instructions * any condition making the patient unsuitable for the study * refusal to be notified in case of incidental finding on the examination wp3: 0.55t prostate mri with patients with suspicious lesion(s) * individuals with a history of prostate cancer. * contraindications as per md instructions * any condition making the patient unsuitable for the study * refusal to be notified in case of incidental finding on the examination
predictive factors of disease-free survival after complete pathological response to neoadjuvant radiotherapy in rectal adenocarcinoma

Conditions: Rectal Neoplasms

Summary: many data suggest that patients with low rectal adenocarcinoma who achieved ypt0n0 status have improved survival and disease-free survival (dfs) compared to all other stages however only few data are available regarding the specific prognosis factors of this subgroup. this retrospective multicentric study aimed to predict the prognosis of patients with complete pathological response after neoadjuvant treatment.


Eligibility criteria:
inclusion criteria * patients with a histologically proven low rectal adenocarcinoma, * no previous or synchronous colorectal disease, * uicc stage i-iii patients who underwent neoadjuvant chemoradiotherapy or chemotherapy, * followed by total mesorectal excision (tme), and * a complete pathological response defined as ypt0n0 exclusion criteria: - all patients with metastatic tumors or missing data

Keywords: low rectal cancer neoadjuvant treatment complete pathological response ypt0n0 disease free survival predictive factors
a study to evaluate molnupiravir (mk-4482) in participants with moderate hepatic impairment (mk-4482-016)

Conditions: Hepatic Impairment

Summary: the purpose of this study is to evaluate the pharmacokinetics (pk) of n-hydroxycytidine (nhc) following a single oral dose of molnupiravir in participants 18 to 75 years (inclusive) with moderate hepatic impairment and healthy matched controls.


Eligibility criteria:
the key inclusion and exclusion criteria include but are not limited to the following: inclusion criteria: * has a bmi ≥18.5 and ≤35 kg/m2 * diagnosis of chronic (\>6 months) stable hepatic impairment (hi) with features of cirrhosis due to any etiology (moderate hi arm only) * has a score on the child-pugh scale ranging from 7 to 9 (moderate hi arm only) * in good health (except for moderate hi) exclusion criteria: * anticipated survival of \<3 months (moderate hi arm only) * received antiviral and/or immune modulating therapy (moderate hi only) for hepatitis b virus (hbv) or hepatitis c virus (hcv) within 90 days prior to study start * history of clinically significant abnormalities or diseases (healthy matched arm only). * history of cancer * major surgery and/or donated or lost 1 unit of blood * taking medications to treat chronic medical conditions and has not been on a stable regimen for at least 1 month (moderate hi arm only) and/or is unable to withhold the use of the medication(s) within 4 hours prior to and 8 hours after administration of the study drug.
development of the effectiveness of rehabilitation tools for neurovisual disorders in patients with posterior cortical atrophy

Conditions: Posterior Cortical Atrophy

Summary: posterior cortical atrophy (pca) is manifested by neuro-visual disorders that alter the spatial location of objects, their manipulation and/or recognition. its etiology is most often neurodegenerative, with a major impact on the autonomy and mood of patients and their families. few studies have focused on non-medication management of these disorders. the present study thus has a double objective: the development of a complete tool to work on the recognition, localization and/or manipulation of objects; and the evaluation of the effectiveness of this type of management.


Eligibility criteria:
inclusion criteria: * age \>50 years old * male or female * patients with a diagnosis of pca according to the criteria of tang-wai et al (2004) * mms\>15 * voluntary, written and informed consent of the patient himself or its legal representative (guardian/curator), with oral consent of the patient in all cases * anti-alzheimer's and psychotropic treatments stable for one month, if taken by the patient * affiliation to a social security system exclusion criteria: * uncorrected visual disorders with non-degenerative etiology (av\<0.5) * person under the protection of justice * pregnant women (a pregnancy test will be performed in premenopausal women)
using chatgpt as a job coach for adults with autism spectrum disorder

Conditions: Autism; Job Interview Performance

Summary: the goal of this clinical trial is to examine the effectiveness of the chatgpt-based job coach in helping asd individuals prepare for job application, job interview, and interpersonal skills in workplaces. the main questions aim to answer are: how can we develop a chatgpt-based job coach system to assist individuals with autism spectrum disorder (asd) in job applications, job interviews, and interpersonal skills in workplaces? how effective is the chatgpt-based job coach in helping asd individuals (n=30) prepare for job applications, job interviews, and interpersonal skills in workplaces? what clinical correlates are associated with better effectiveness, and what are the interaction patterns between asd adults and the chatgpt platform? participants will complete assessment questionnaires (evaluating autism traits and empathy, approximately 30 minutes) and a one-hour job interview practice. please follow the recommendations to use chatgpt for completing your job resume, job type discussions, job interview preparation and practice, explanation of asperger's traits for the workplace, and workplace social discussions. after one week of practice, you will fill out the assessment questionnaires and complete the job interview practice again.


Eligibility criteria:
inclusion criteria: * young adult aged between 18 and 45 years who had a diagnosis of asd from a licensed mental health or medical professional based on dsm-5; * is motivated to have a job * is able to use the chatgpt on the computer under instruction (e.g., typing questions) and is able to provide feedback to the research team * has a full-scale iq \> 70 on wais-iv * scored ≧ 26 on the caregiver-reported autism spectrum quotient (aq), indicating clinical impairment associated with asd * agree to audio and video recording during the interview rehearsal. exclusion criteria: * a history of major psychiatric disorders (e.g., bipolar affective disorder, schizophrenia, or psychosis) or neurological diseases * visual impairment and/or hearing impairment that would preclude participation in the study * refuse audio and video recording during the interview rehearsal.
cook enforcer post-market study

Conditions: End-Stage Renal Disease

Summary: the purpose of this study is to evaluate the performance of the cook advance® enforcer™ 35 focal-force pta balloon catheter (or enforcer balloon) in treating narrowed blood vessels compared to treatment with a conventional angioplasty balloon.


Eligibility criteria:
inclusion criteria: * clinical or physiological abnormalities which indicate dialysis access dysfunction (e.g., decreased access blood flow, elevated venous pressure, decreased dialysis dose, abnormal physical exam) exclusion criteria: * less than 18 years old * pregnant, lactating, or planning to become pregnant in the 3 months following enrollment * underwent any surgical or interventional procedure of the access circuit less than or equal to 30 days prior to enrollment * scheduled for a kidney transplant * stent or stent graft in the arteriovenous (av) dialysis access circuit

Keywords: dialysis renal hemodialysis stenosis(es) transluminal percutaneous transluminal angioplasty
efficacy study of tepso® socks in improving palmoplantar pustulosis

Conditions: Pustulosis of Palms and Soles

Summary: the purpose of this study is to evaluate the efficacy of a special sock, manufactured using tepso®, compared to a normal cotton sock in the prognosis of symmetrical palmoplantar pustulosis present for at least one year.

the clinical manifestations of palmoplantar pustulosis have an important impact on well being and quality of life. the manifestation of the disease is often exacerbated by factors such as significant physical and mechanical stress resulting from repeated and prolonged pressure over the affected areas and by everyday clothing. these problems have led the textile industry lenzi egisto s.p.a. to conduct some preliminary analyses to find a fabric that meets the specific needs of psoriatic patients in relation to everyday clothing. this preliminary study led to the creation of a particular fabric, tepso®, with features specific to the identified needs. this material consists essentially of ptfe (commercially known as teflon®) and thus presents interesting characteristics that make it suitable for creating garments for patients with psoriasis: * excellent flow properties and low surface friction * non-stick * complete biocompatibility and chemical inertness we can therefore speculate that in palmoplantar pustulosis high smoothness of the fabric and low coefficient of friction may translate into less discomfort felt by patients during normal physical activities, and into improved clinical course of the disease. in the end, it is expected that reduced mechanical compression and friction, would result into partial or complete clinical remission within a few weeks of use. therefore we propose to conduct a randomized controlled, double-blind, left-right clinical trial to assess the hypothesis that in palmoplantar pustulosis the use of tepso® could induce an improvement of disease and overall quality of life. to better assess the effects of treatment, the use of clothing in the study will be limited to symmetrical pustular lesions of feet in order to include areas that are comparable and relevant from a functional point of view.

Eligibility criteria:
inclusion criteria: * palmoplantar pustulosis present for at least one year * symmetrical foot lesions with at least 5% of the skin surface involvement * difference less than or equal to 10% extension of lesions on both sides of the body * suspension for over 3 months from start of the study of any systemic drugs for psoriasis, immunosuppressive treatments (cyclosporine, systemic steroids), psoralen plus ultraviolet a irradiation (puva) or ultraviolet b phototherapy (uvb) exclusion criteria: * nonsymmetrical foot lesions or less than 5% of the skin surface involvement * difference of more than 10% extension of lesions on both sides of the body * patients who have performed, within 3 months before inclusion in the study, treatments with systemic drugs for psoriasis, immunosuppressive treatments (cyclosporine, systemic steroids), psoralen plus ultraviolet a irradiation (puva) or ultraviolet b phototherapy (uvb)

Keywords: pustulosis soles teflon
combination therapy with fludarabine, mitoxantrone and rituximab in mantle cell lymphoma

Conditions: Mantle Cell Lymphoma

Summary: this study is being done in order to determine the effectiveness of the combination of fludarabine, mitoxantrone, and rituximab in patients with mantle cell lymphoma. all three drugs,fludarabine, mitoxantrone, and rituximab have been approved by the u.s. food and drug administration (fda)for the treatment of certain types of lymphoma. rituximab is a drug (called a monoclonal antibody) which has anti-tumor activity on certain types of lymphoma. the combination of chemotherapy (fludarabine and mitoxantrone) with rituximab has not yet been investigated in patients with mantle cell lymphoma and therefore the combination in investigational.


Eligibility criteria:
inclusion criteria: * pathologic diagnosis of non-hodgkin's lymphoma of the mantle cell sub-type lymphoma only, as determined by morphologic assessment and consistent immunophemotypic markers * newly diagnosed and patients who have received prior treatment are eligible * measurable or evaluable disease * karnofsky performance status greater or equal to 50% * men and women, age greater or equal to 18 years old * agc greater or equal to 1.0; platelets greater or equal to 75,000; hemoglobin greater or equal to 8.0 (unless because of lymphomatous infiltration of the marrow) * creatinine less than 2.0; bilirubin less than 2.0; sgot less than 3 times upper limit of normal (unless elevations are due to lymphomatous involvement) * women of child bearing potential must have negative pregnancy test within 14 days of study entry. * signed informed consent exclusion criteria: * history of congestive heart failure or significant cardiac disease * prior exposure to either fludarabine or mitoxantrone. prior exposure to rituximab allowed * active infection * hiv seropositive * pregnant or lactating females * second active malignancy, other than squamous cell skin cancer,in-situ cervical cancer, or history of other cancer diagnosed within the preceding 5 years * presence of psychological or emotional disorders which would make valid informed consent impossible
controlled myelofibrosis study with oral jak inhibitor treatment: the comfort-i trial

Conditions: MPN (Myeloproliferative Neoplasms)

Summary: this was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib (incb018424) tablets to matching placebo tablets in patients diagnosed with myelofibrosis (either primary myelofibrosis (pmf) or post-polycythemia vera myelofibrosis (ppv-mf) or post-essential thrombocythemia myelofibrosis (pet-mf).

patients with spleen growth of greater than 25% based on an increase in spleen volume from baseline were eligible for early unblinding, and for patients on placebo, cross over to ruxolitinib prior to the primary study endpoint being reached. if this spleen growth occurred before week 24, it must have been accompanied by specific worsening of symptoms, based on worsening early satiety accompanied by weight loss or worsening pain requiring daily narcotic use. after week 24, asymptomatic spleen growth alone was sufficient for early unblinding and potential cross over. patients found to have been randomized to ruxolitinib after early unblinding prior to week 24 were discontinued. when half of the patients remaining in the study completed the week 36 visit and all patients enrolled completed week 24 or discontinued, the database was frozen and the primary analysis was conducted. once this was complete, all patients were unblinded and patients who had been randomized to placebo were given the opportunity to cross over to ruxolitinib treatment, provided hematology laboratory parameters were adequate; patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed week 144 (36 months).

Eligibility criteria:
inclusion criteria: * subjects must be diagnosed with primary myelofibrosis (pmf), post-polycythemia vera-myelofibrosis (ppv-mf) or post-essential thrombocythemia-myelofibrosis (pet-mf) according to the 2008 world health organization criteria * subjects with myelofibrosis requiring therapy must be classified as high risk or intermediate risk level 2 according to the prognostic factors defined by the international working group * subjects with an eastern cooperative oncology group (ecog) performance status of 0, 1, 2 or 3 * subjects who have not previously received treatment with a janus kinase (jak) inhibitor exclusion criteria: * subjects with a life expectancy of less than 6 months * subjects with inadequate bone marrow reserve as demonstrated by specific clinical laboratory counts * subjects with inadequate liver or renal function * subjects with clinically significant bacterial, fungal, parasitic or viral infection which require therapy * subjects with an active malignancy over the previous 5 years except specific skin cancers. * subjects with severe cardiac conditions * subjects who have had splenic irradiation within 12 months

Keywords: myelofibrosis post-polycythemia vera myelofibrosis post-essential thrombocythemia myelofibrosis
relationship between food insecurity and child dental anxiety

Conditions: Food Insecurity; Child Dental Anxiety; Maternal Psychological Distress

Summary: identifying children with dental anxiety among those who suffered from food insecurity will enable to implement preventive strategies and early intervention. the aim of this study is to examine the relationship between food insecurity, maternal psychological status and child dental behavior.

a well-trained investigator will collect data on maternal age (in years), the marital status, the educational levels of both parents and their employment status, pregnancy information, as well as family structure (whether children are living with both parents or not), number of siblings (none, one, two, or ≥three). information on family monthly income and crowding index which is defined as the average number of people per room, excluding both the kitchen and bathrooms will be also obtained. the level of household food insecurity will be determined using the validated arabic version of the household food insecurity access scale (hfias) which categorizes food insecurity into three levels (food secure , marginally food secure and food insecure) where the final score is given according to the sum of affirmative responses to the tool statements and the higher the score the more the level of food insecurity. the validated arabic version of the 14-item perceived stress scale will be used to measure the self-reported level of stress among mothers of the enrolled children by assessing their feelings and thoughts during the last month. the level of child's dental anxiety will be assessed during the initial oral examination before starting any dental treatment procedures using the six-point venham behavior rating scale which ranges from total cooperation (0) to no cooperation

Eligibility criteria:
inclusion criteria: * the selected children accompanied by their mother should fulfill the following inclusion criteria: * age range 3.5-6 years * having at least one tooth with dental caries indicated for dental treatment under local anesthesia other than extraction * visiting the dental clinic for the first time exclusion criteria: * children with the following criteria will be totally excluded from the study: have any medical/neurological, communicative or developmental disorders as well as children with special healthcare needs.
ppi versus placebo in severe functional heartburn

Conditions: GERD

Summary: proton pump inhibitors are no better than placebo in relieving gerd symptoms in patients with functional heartburn.


Eligibility criteria:
inclusion criteria: * heartburn twice a week for at least 2 years. normal egd and 24hr ph study. exclusion criteria: * \<18yrs of age,pregnant, unable or unwilling to give consent, allergic to ppi, previous gastric or esophageal surgery, past hx of erosive gerd, unwilling or unable to stop acid suppression meds

Keywords: gerd ppi functional heartburn
safety and efficacy of mesenchymal stem cells in newly-diagnosed type 1 diabetic patients

Conditions: Diabetes Mellitus, Insulin-Dependent

Summary: type 1 diabetes mellitus results from the autoimmune destruction of the insulin producing pancreatic β-cells. the autoimmune response begins months or even years before the presentation of hyperglycemic symptoms. previous studies with other autoimmune diseases or acute inflammatory diseases testing the effect of the infusion of mesenchymal stem cells showed promising results in regulating immune system and promoting some degree of disease control. the aim of our study is to determine the safety and efficacy of intravenous infusions of mesenchymal stem cells in newly diagnosed type 1 diabetic patients.

patients from 12 to 35 years old with type i diabetes mellitus proved by anti-pancreatic beta cell antibodies and recently diagnosed (less than 6 weeks) will be included in this study. first, bone marrow derived adult mesenchymal stem cells are collected from a first degree relative and cultured. after that, the patient receive 4 intravenous infusions 1 week apart followed by 4 infusion 4 months apart.

Eligibility criteria:
inclusion criteria: * type 1 diabetes mellitus diagnosed by clinical/metabolic parameters and positive anti-gad antibodies * less than 6 weeks from diagnosis exclusion criteria: * previous diabetic ketoacidosis * pregnancy * severe psychiatric disorder * severe organic impairment (renal, hepatic, cardiac, pulmonary) * active infectious disease * previous or present neoplastic disease

Keywords: diabetes mellitus stem cells autologous stem cell transplantation autoimmune diseases